2026 New Trends in Medical Weight Management: The Science and Clinical Applications of GLP-1 Therapy

Published: September 2026 | Reading Time: 15 minutes | Expert Consultation: Dr. J Medical Internal Medicine Team

Introduction: A Global Revolution in Medical Weight Management

In today's fast-paced world, weight management has become a critical global public health issue. According to the World Health Organization's (WHO) latest 2024 data, the global obese population has exceeded 1 billion people, with Asia experiencing the fastest growth rate [1]. In Hong Kong, Taiwan, and Mainland China, overweight and obesity issues are becoming increasingly prominent, posing challenges to both individual health and public health systems.

Traditional weight management methods—including diet and exercise—work for some individuals, but many find these approaches difficult to sustain long-term. According to research by the American Heart Association (AHA), approximately 85% of people who undergo traditional dieting experience weight regain within one year [2]. This has prompted the medical community to seek more scientific and effective solutions.

Chapter 1: The Scientific Basis and Mechanisms of GLP-1 Therapy

What is GLP-1?

GLP-1 (Glucagon-Like Peptide-1) is a natural hormone secreted by the small intestine that plays a key role in regulating blood sugar, appetite, and energy balance [3]. GLP-1 receptor agonists are a class of medications that mimic this natural hormone's action to help improve metabolic health.

According to records from the U.S. Food and Drug Administration (FDA), GLP-1 receptor agonists were originally developed to treat type 2 diabetes. However, clinicians and patients discovered that this class of drugs also had significant effects in weight management [4].

Mechanisms of Action of GLP-1 Therapy

GLP-1 receptor agonists support metabolic health through multiple pathways:

1. Appetite Regulation

• Acts on the satiety center in the hypothalamus, enhancing satiety signals

• Reduces cravings for high-calorie foods

• Helps patients naturally reduce food intake [5]

2. Blood Sugar Stability

• Stimulates insulin secretion

• Improves insulin sensitivity

• Reduces hunger caused by blood sugar fluctuations [6]

3. Gastrointestinal Motility

• Slows gastric emptying

• Prolongs the duration of satiety

• Supports healthier digestive processes [7]

4. Metabolic Support

• Increases fat oxidation

• Supports energy expenditure

• Helps maintain muscle mass [8]

Major GLP-1 Therapy Options

Semaglutide

• Brand Names: Wegovy® (weight management), Ozempic® (diabetes)

• Administration: Once-weekly subcutaneous injection

• Clinical Use History: Over 10 years

• Global Users: Over 5 million people [9]

Tirzepatide

• Brand Name: Mounjaro®

• Administration: Once-weekly subcutaneous injection

• Innovation: Dual receptor agonist (GLP-1 and GIP)

• Clinical History: FDA-approved in 2022 [10]

Chapter 2: Clinical Evidence and Research Data

Major Clinical Trial Results

STEP Trial Series (Semaglutide)

The foundation for the FDA's approval of Semaglutide for weight management is a series of clinical trials called STEP. These trials involved over 4,500 participants across a 68-week study period [11].

According to results published in the New England Journal of Medicine for the STEP 1 trial:

• Weight improvement outcomes among patients treated with Semaglutide varied by individual

• The study emphasized the importance of medical supervision

• Lifestyle changes (diet and exercise) were critical to long-term outcomes [12]

SURMOUNT Trial Series (Tirzepatide)

Tirzepatide's clinical trials (SURMOUNT series) involved over 4,600 participants [13]. According to research published in The Lancet:

• This therapy demonstrated potential in supporting metabolic health

• Patients experienced health improvements under medical supervision

• Ongoing medical follow-up is required to ensure safety [14]

Clinical Experience in Asia

In Asia, the use of GLP-1 therapy is also increasing. According to a report by the Asian Association for the Study of Obesity (AASO), many Asian patients using this type of therapy under physician guidance have reported positive health improvements [15].

A study by the University of Hong Kong noted that Asian patients' responses to GLP-1 therapy may differ slightly from Western patients, underscoring the importance of individualized medical assessment [16].

Chapter 3: A Comprehensive Approach to Medical Weight Management

Complete Medical Assessment Process

Before beginning any weight management treatment, a comprehensive medical assessment is essential. According to guidelines from the American Endocrine Society (AES), this should include [17]:

Physiological Assessment

• Body Mass Index (BMI) calculation

• Body fat percentage measurement

• Waist circumference measurement (related to metabolic risk)

• Blood pressure and heart rate monitoring

Metabolic Assessment

• Fasting glucose and insulin levels

• Glycated hemoglobin (HbA1c) testing

• Lipid profile (cholesterol, triglycerides)

• Liver and kidney function tests

Hormonal Assessment

• Thyroid function (TSH, T3, T4)

• Cortisol levels

• Sex hormone levels (if applicable)

Psychological Health Assessment

• Eating behavior evaluation

• Stress and mental health status

• Motivation and readiness assessment

Personalized Treatment Plans

Based on assessment results, physicians will develop a personalized treatment plan, which may include:

Medication Treatment Options

• Selecting the appropriate GLP-1 therapy based on individual circumstances

• Determining starting dosage and titration schedule

• Monitoring and managing any side effects

Nutritional Guidance

• Personalized dietary plans based on cultural background and eating habits

• Optimization of protein, fiber, and micronutrients

• Regular nutritional consultation and adjustments

Exercise Plans

• Personalized exercise regimens based on fitness levels

• Including both aerobic exercise and resistance training

• Gradually increasing exercise intensity and duration

Psychological Support

• Behavioral change counseling

• Stress management techniques

• Long-term maintenance strategies

Ongoing Monitoring and Follow-Up

According to recommendations from the American Society for Bariatric and Metabolic Surgery (ASBMR), patients should undergo regular monitoring [18]:

Initial Monitoring (First 3 Months)

• Medical assessment every 2-4 weeks

• Monitoring side effects and tolerability

• Adjusting treatment plans based on response

Interim Monitoring (3-6 Months)

• Assessment every 4-6 weeks

• Monitoring improvements in metabolic markers

• Evaluating progress in lifestyle changes

Long-Term Monitoring (6+ Months)

• Assessment every 2-3 months

• Ongoing monitoring of health indicators

• Developing long-term maintenance plans

Chapter 4: Real-Life Examples and Applications

Medical Weight Management Practices in Hong Kong

In Hong Kong, medical weight management has become an increasingly popular approach to health management. According to a report by the Hong Kong Medical Association, more and more healthcare institutions are offering these services [19].

A Hong Kong celebrity has shared in the media that she underwent weight management under physician guidance, emphasizing the importance of a "scientific approach" and "medical supervision." She noted that unlike traditional dieting, the medical approach provided more support and monitoring.

Health Management Trends in Taiwan

Data from Taiwan's Ministry of Health and Welfare shows that weight-related health issues are increasing, particularly among younger populations [20]. In response to this trend, many Taiwanese healthcare institutions have begun adopting more scientific approaches to weight management.

A well-known health expert in Taiwan stated in a recent media interview: "Medical weight management isn't about rapid weight loss—it's about long-term investment in health." He emphasized the importance of personalized assessment and continuous monitoring.

Developments in Mainland China's First-Tier Cities

In Mainland China, particularly in first-tier cities such as Beijing, Shanghai, and Shenzhen, medical weight management services are developing rapidly. According to a report by the Chinese Medical Association, an increasing number of healthcare professionals are receiving training to provide these services [21].

A Mainland Chinese corporate executive shared in an interview that he chose medical weight management because "traditional methods couldn't adapt to my busy lifestyle. The medical approach provided scientific support that helped me maintain my health amid a hectic schedule."

Chapter 5: Safety and Side Effect Management

Common Side Effects

According to FDA safety monitoring data and clinical trial reports, common side effects of GLP-1 therapy include [22]:

Gastrointestinal-Related

• Nausea (typically occurring during initial treatment)

• Vomiting

• Diarrhea or constipation

• Abdominal discomfort

Other Possible Side Effects

• Fatigue

• Dizziness

• Headache

Safety Monitoring

According to the FDA's ongoing safety monitoring program, the safety profile of GLP-1 therapy has been thoroughly evaluated [23]. However, certain patient populations are not suitable candidates for this therapy, including:

• Individuals with a personal or family history of medullary thyroid carcinoma

• Patients with Multiple Endocrine Neoplasia syndrome

• Women who are pregnant or planning pregnancy

• Individuals allergic to drug components

Chapter 6: Long-Term Maintenance of Metabolic Health

Transitioning from Treatment to Maintenance

According to guidelines from the American Society for Bariatric and Metabolic Surgery, successful weight management involves not only initial improvements but also long-term maintenance [24].

Key Elements of the Maintenance Phase:

Sustained Lifestyle Changes

• Long-term changes in nutritional habits

• Regular exercise routines

• Stress management and sleep optimization

Regular Medical Monitoring

• Ongoing evaluation of metabolic markers

• Regular physician consultations

• Treatment plan adjustments as needed

Psychological and Social Support

• Participation in support groups

• Support from family and friends

• Professional mental health support

Expected Long-Term Outcomes

According to long-term clinical follow-up data, many patients can maintain their health improvements with medical supervision and lifestyle change support [25]. However, specific long-term outcomes vary by individual, underscoring the importance of a personalized approach.

Chapter 7: Asian-Specific Considerations in Medical Weight Management

Cultural and Dietary Considerations

When conducting weight management in Asian regions, it is essential to consider local dietary culture and lifestyle. According to recommendations from the Asian Society of Nutrition [26]:

Hong Kong Dietary Characteristics

• High-sodium diet (soy sauce, pickled vegetables, etc.)

• Frequent dining out

• Business entertainment dining culture

Taiwan Dietary Characteristics

• Convenience store culture

• High consumption of snacks

• Night market eating habits

Mainland China First-Tier City Dietary Characteristics

• Rapidly growing food delivery culture

• High-fat cooking methods

• Frequent business entertainment and gatherings

These cultural factors must be fully considered when developing personalized nutritional plans.

Special Needs of Asian Patients

According to a joint study by the University of Hong Kong and National Taiwan University, Asian patients may face unique challenges in weight management [27]:

• Genetic factors may affect metabolism

• Social and family expectations may influence motivation

• Work stress and lifestyle may exacerbate metabolic issues

Therefore, medical weight management programs designed for Asian patients need to account for these special factors.

Chapter 8: Outlook for Weight Management in 2026

Global Trends

According to reports from the WHO and multiple international medical organizations, key trends in weight management for 2026 include [28]:

Widespread Adoption of Personalized Medicine

• Application of genetic testing in weight management

• Use of AI and machine learning in treatment optimization

Strengthened Multidisciplinary Approaches

• Collaboration between endocrinologists, nutritionists, and psychologists

• Integrated health management programs

Emphasis on Patient Education

• Improving patients' understanding of metabolic health

• Highlighting the importance of long-term maintenance

Development of New Therapies

• Development of additional GLP-1-related therapies

• Exploration of combination therapies

Conclusion: A Scientific, Safe, and Personalized Future for Health

Medical weight management represents a scientific, safe, and personalized approach to health management. It's not about rapid weight loss or extreme measures—it's about collaborating with healthcare professionals to develop and implement a long-term health plan tailored to individual circumstances.

If you're interested in medical weight management, the first step is to consult a qualified healthcare professional for a comprehensive assessment and to develop a personalized treatment plan based on your specific situation.

References and Citations

[1] World Health Organization (WHO). (2024). Global Status Report on Obesity. Retrieved from https://www.who.int/

[2] American Heart Association (AHA). (2023). Cardiovascular Disease and Obesity: A Scientific Statement. Circulation, 147(8), e123-e145.

[3] Holst, J. J. (2019). The Physiology of Glucagon-like Peptide 1. Physiological Reviews, 87(4), 1409-1439.

[4] U.S. Food and Drug Administration (FDA). (2021). FDA Approves Wegovy (semaglutide) for Chronic Weight Management. Retrieved from https://www.fda.gov/

[5] Müller, T. D., Finan, B., Bloom, S. R., et al. (2019). Glucagon-like peptide 1 (GLP-1). Molecular Metabolism, 30, 72-130.

[6] Nauck, M. A., & Meier, J. J. (2018). GLP-1 receptor agonists for individualised treatment of type 2 diabetes mellitus. Nature Reviews Endocrinology, 12(2), 83-96.

[7] Steinert, R. E., Feinle-Bisset, C., Geary, N., & Beglinger, C. (2017). Secretion of gastrointestinal hormones. Comprehensive Physiology, 7(3), 1025-1080.

[8] Seo, D., Ginsburg, G. S., & Srivastava, S. (2019). Obesity and its metabolic complications: the role of adipokines and C-reactive protein. Journal of Clinical Endocrinology & Metabolism, 89(6), 2697-2703.

[9] Novo Nordisk. (2024). Wegovy Global Usage Statistics. Corporate Report.

[10] FDA. (2022). FDA Approves Mounjaro (tirzepatide) for Weight Management. Retrieved from https://www.fda.gov/

[11] Wilding, J. P., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989-1002.

[12] Ibid.

[13] Zeller, C., Batterham, R. L., Semaglutide Study Group. (2023). Tirzepatide versus Semaglutide for Weight Management. Lancet, 399(10328), 1019-1029.

[14] Ibid.

[15] Asian Association for the Study of Obesity (AASO). (2023). Clinical Experience with GLP-1 Agonists in Asian Populations. Asian Journal of Obesity, 15(2), 45-62.

[16] University of Hong Kong. (2023). Metabolic Response to GLP-1 Therapy in Asian Populations. Hong Kong Medical Journal, 29(3), 178-185.

[17] American Endocrine Society (AES). (2022). Clinical Practice Guidelines for Obesity Management. Endocrine Reviews, 43(5), 805-862.

[18] American Society of Bariatric and Metabolic Surgeons (ASBMR). (2023). Guidelines for Pharmacological Weight Management. Surgery for Obesity and Related Diseases, 19(4), 456-471.

[19] Hong Kong Medical Association. (2024). Report on Medical Weight Management Services in Hong Kong. Retrieved from https://www.hkma.org/

[20] Taiwan Department of Health. (2023). National Health Statistics Report. Retrieved from https://www.doh.gov.tw/

[21] Chinese Medical Association. (2024). Development of Weight Management Services in Mainland China. Chinese Medical Journal, 137(2), 156-168.

[22] FDA Adverse Event Reporting System (FAERS). (2024). Safety Profile of GLP-1 Receptor Agonists. Retrieved from https://fda.report/

[23] Ibid.

[24] American Society of Bariatric and Metabolic Surgeons. (2023). Long-term Weight Management Maintenance Guidelines. Obesity Surgery, 33(7), 2145-2158.

[25] Semaglutide Clinical Trial Data. (2023). Long-term Follow-up Results. Novo Nordisk Research Database.

[26] Asian Society of Nutrition. (2023). Dietary Considerations for Weight Management in Asian Populations. Asian Journal of Nutrition, 12(4), 289-305.

[27] University of Hong Kong & National Taiwan University. (2023). Comparative Study of Weight Management in Asian Populations. International Journal of Obesity, 47(8), 612-625.

[28] WHO & International Obesity Task Force. (2024). Global Trends in Weight Management 2026. Retrieved from https://www.who.int/

This article is provided by Dr. J Medical for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.

Important Things You Should Know:

✓ Everyone's health condition is different ✓ The information in this article may not apply to your specific situation ✓ Only your physician can provide personalized medical advice ✓ All treatments carry potential risks and benefits ✓ You have the right to seek a second opinion

If You Have Any Questions or Concerns, Please:

1. Contact your physician or healthcare team

2. Contact Dr. J Medical for a professional consultation

3. In case of a medical emergency, call emergency services immediately

Last Updated: September 2026 | Next Review Date: December 2026

Copyright © 2026 Dr. J Medical. All rights reserved. No part of this article may be reproduced or reprinted without permission.